Skip to main content
Premium Trial:

Request an Annual Quote

Binx Health Raises $104M in Series E Round

NEW YORK — Binx Health said on Thursday that it has raised $104 million in a Series E financing round.

The round was led by OrbiMed and included existing investors LSP and Johnson and Johnson Development, as well as new investors Arrowmark Partners, Hildred Capital Management, Alta Life Sciences, and Parian Global. In connection with the financing, Andrew Goldman, Hildred's cofounder and managing partner, is joining Binx's board.

Binx said it will use the funding to expand manufacturing of its US Food and Drug Administration-cleared Binx io molecular point-of-care instrument and accompanying chlamydia and gonorrhea tests, which received CLIA waivers from the FDA in March.

The Boston-based company said the money will also be used to develop new tests for the instrument, expand its sales operations in the US and overseas, and advance its software platform and data infrastructure.

Earlier this year, Binx said that it is aiming to strike deals to offer its tests through retailers, with an announcement about a collaboration with an undisclosed retail chain forthcoming.

The Scan

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.

Active Lifestyle Linked to Type 2 Diabetes Prevention in People at High Genetic Risk

A study in the British Journal of Sports Medicine shows that an active lifestyle goes a long way in type 2 diabetes prevention.

Beneficial, Harmful Effects of Introgression Between Wild and Domesticated European Grapes

A paper in PNAS shows that European wild grapevines were an important resource for improving the flavor of cultivated wine grapes.

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.